Back to Agency Updates
Health and Human Services DepartmentCenters for Disease Control and Prevention
  • By Learn Laws®
  • Published 04/28/2026
  • Updated 04/29/2026

CDC Proposes New Data Collection for Fragile X Syndrome Under FAST FORWARD Project


The Centers for Disease Control and Prevention (CDC), an agency within the Department of Health and Human Services (HHS), has announced a public comment period for a proposed information collection project. This initiative, titled Focus on Advancing Support and Transition with the Fragile X Online Registry With Accessible Database (FAST FORWARD), aims to gather critical data concerning individuals with Fragile X Syndrome (FXS).

Published in the Federal Register on April 28, 2026, this notice invites comments on the proposed surveillance project. The CDC's objective is to enhance its understanding of health, educational, and social outcomes, pinpoint gaps in related services such as education and employment, and identify barriers to healthcare and other services for people living with FXS. The public comment period will remain open until June 29, 2026, allowing stakeholders to submit feedback via the Federal eRulemaking Portal at regulations.gov or by mail.

Understanding Fragile X Syndrome

Fragile X Syndrome is a genetic condition resulting from alterations in the FMR1 gene, which typically produces Fragile X Messenger Ribonucleoprotein (FMRP), essential for brain development. Individuals with FXS produce little to no FMRP. It stands as the most common inherited cause of intellectual disability and the leading monogenic cause of autism. The syndrome presents with a range of features, including distinct physical characteristics like a narrow face, prominent jaw and forehead, and large ears. Medical concerns can include dental crowning, recurrent ear infections, sinus infections, sleep disturbances, and strabismus. Developmental challenges often encompass intellectual disability, motor delays, poor eye contact, repetitive behaviors, seizure disorders, speech-language difficulties, and symptoms akin to attention deficit hyperactivity disorder. Diagnosis typically occurs in early childhood as these features become more recognizable. Estimates suggest that FXS affects approximately one in 7,000 males and one in 11,000 females.

Building on Past Research

The FAST FORWARD project represents a continuation and enhancement of four prior CDC-funded data collection efforts focused on FXS. The earliest project, from 2008 to 2011, established an infrastructure for data collection across multiple sites. A subsequent project from 2011 to 2015 developed and piloted the framework for a registry and longitudinal data collection. These foundational efforts led to the creation of the Fragile X Online Registry With Accessible Research Database (FORWARD) from 2015 to 2020. The most recent phase, FORWARD-MARCH (Multiple Assessments for Research Characterization), running from 2021 to 2026, extended FORWARD to collect further data to characterize the natural history of FXS and identify meaningful outcome measures to improve the lives of those affected.

Congressional Intent and Project Objectives

The current proposal for FAST FORWARD directly addresses language included in the 2026 Consolidated Appropriations Act. This Congressional directive encouraged the CDC to pursue additional strategies aimed at promoting earlier identification of children with FXS, ensuring proper diagnosis, raising awareness of available medical services, and supporting individuals with FXS and associated conditions throughout their lives. Consistent with this legislative intent, FAST FORWARD will employ clinic-based enrollment, targeting eligible participants aged 40 years or younger who have a full mutation of FXS and attend one of the three U.S. clinics funded for this project. The goal is to recruit a minimum of 200 eligible persons with FXS per clinic, totaling approximately 600 participants across all three sites over the project's duration. Information will be collected on a wide array of topics, including diagnosis, co-occurring conditions and behaviors, communication, adaptive abilities, healthcare utilization and service needs, education, transition planning and experience, activities and social participation, future planning, caregiver supports, demographics, and participant strengths. Data will be primarily gathered through online caregiver surveys.

The Role of Public Comment

Under the Paperwork Reduction Act of 1995, federal agencies must obtain approval from the Office of Management and Budget (OMB) for information collection efforts and provide a 60-day notice in the Federal Register for proposed collections. The CDC's request for public comments is a critical step in this process. The OMB is particularly interested in feedback that helps evaluate the necessity and practical utility of the proposed information collection, assess the accuracy of the agency's burden estimate for respondents, enhance the quality and clarity of the information to be collected, and explore ways to minimize respondent burden through technological means. This public engagement ensures transparency and accountability in federal data collection practices, allowing for refinement and optimization of the project before its full implementation. The estimated annual burden for respondents is 600 hours, with no direct costs to participants beyond their time.

The FAST FORWARD project represents a significant federal effort to deepen the understanding of Fragile X Syndrome and its lifelong impacts. By meticulously collecting data on a wide spectrum of life aspects for individuals with FXS, the CDC aims to generate evidence that can inform more effective public health strategies, refine diagnostic pathways, and enhance the provision of supportive services. The success of this initiative hinges on robust data collection and analysis, which in turn relies on the continued engagement of both the medical community and affected families.

Learn More

We are an education company, not a law firm. The information and content we provide is for general informational purposes only and does not constitute legal advice. We make no representations, warranties, or guarantees regarding the accuracy, completeness, or applicability of the content. It is important to always consult with a qualified attorney for specific legal counsel pertaining to your individual circumstances.

People Also Viewed...

DOT Reasonable Suspicion Training for Supervisors

$60.00

Non-DOT Reasonable Suspicion Training for Supervisors

$55.00

Drug-Free Workplace Training for Employees

$35.00